LQDA vs WST
Liquidia Corporation vs West Pharmaceutical Services — AI-powered side-by-side comparison
LQDA
Liquidia Corporation
68
Buy
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | LQDA | WST |
|---|
| AI Score |
68
|
74
|
| Price |
$88.09
|
$351.74
|
| P/E Ratio |
368.26×
|
44.65×
|
| ROE |
-154.0%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.8%
|
36.8%
|
| Debt / Equity |
1.70×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
55.0
|
58.0
|
| Beta |
0.572
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for LQDA versus WST.
WST leads by 6 points.
WST scores 74/100 (Buy) versus LQDA at 68/100 (Buy).
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical